5 news items
Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
SRZN
12 Jun 24
for such product candidate to be used to treat human disease, as well as the potential benefits of such product candidate), and the Company's
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
SRZN
10 Jun 24
, as well as the potential benefits of such product candidates), and the Company's partnership with Boehringer Ingelheim, including the potential
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
SRZN
4 Jun 24
years. I am very excited about the potential for SZN-043 to offer a meaningful clinical benefit to these patients." About SZN-043
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
SRZN
9 May 24
the potential for such product candidate to be used to treat human disease, as well as the potential benefits of such product candidate), and the Company's
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
SRZN
3 Apr 24
as the potential benefits of such product candidates), and the Company's partnership with Boehringer Ingelheim, including the potential for future success
- Prev
- 1
- Next